AbbVie Inc. (ABBV) Earnings Call Analysis

NYSE · Healthcare · Drug Manufacturers - General

23/25

Growth 5 Margin 5 Expansion 5 Platform 3 Financial 5

latest quarter score

Earnings Reports

23
AbbVie (ABBV) Q2 2026: Skyrizi Rises 24% as Immunology, Pipeline Depth Drive $600M Guidance Lift
July 31, 2026
24
AbbVie (ABBV) Q4 2025: Immunology Powerhouses Drive $8B+ Growth, Neuroscience and Oncology Upside Signals Multi-Year Runway
June 15, 2026
24
AbbVie (ABBV) Q1 2026: Immunology Surges 29%, Pipeline and CapEx Signal Decade-Long Growth Bet
April 29, 2026
24
AbbVie (ABBV) Q3 2025: SkyRizi and RINVOQ Surge 40% as Neuroscience Drives Diversified Growth
October 31, 2025
24
AbbVie (ABBV) Q2 2025: Ex-Humira Platform Surges 22%, Raising Full-Year Revenue Target by $1.5B
July 31, 2025
23
AbbVie (ABBV) Q1 2025: Immunology and Neuroscience Outperform as Humira Declines Sharpen
June 10, 2025
AbbVie (ABBV) Q3 2024: Ex-Humira Platform Grows 18% as Pipeline and Portfolio Reshape Post-LOE Trajectory
October 30, 2024
AbbVie (ABBV) Q2 2024: Ex-Humira Platform Delivers $6B Growth as Immunology, Neuroscience Outperform
July 25, 2024
AbbVie (ABBV) Q1 2024: Ex-Humira Platform Surges 15%, Offsetting Biosimilar Erosion
April 26, 2024
AbbVie (ABBV) Q4 2023: Ex-Humira Growth Platform Surges 15%, Powering Post-LOE Recovery
February 02, 2024
21
AbbVie (ABBV) Q3 2023: Ex-Humira Platform Surges 12%, Raising 2024 Earnings Floor
October 27, 2023
AbbVie (ABBV) Q2 2023: Growth Platform Lifts Guidance by $1.4B as Humira Erosion Stabilizes
July 27, 2023
AbbVie (ABBV) Q1 2023: Skyrizi and Rinvoq Surge 46%+ as Humira Erosion Contained
April 27, 2023

Browse all companies